Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Metformin Plus Neoadjuvant Chemotherapy in Breast Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2012 by Instituto Nacional de Cancerologia de Mexico.
Recruitment status was:  Not yet recruiting
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Information provided by (Responsible Party):
Claudia Arce Salinas, Instituto Nacional de Cancerologia de Mexico Identifier:
First received: March 22, 2012
Last updated: March 29, 2012
Last verified: March 2012

Background Obesity and overweight are well known risk factors for breast cancer and also are associated with higher recurrence and mortality rates.

Main goal of this study is to evaluate the efficacy of metformin plus chemotherapy in terms of pathologic complete response in comparison with placebo plus the same chemotherapy regimen Design: Randomized, double blind, clinical trial. This study will be performed at National Cancer Institute of Mexico City, at breast cancer unit.

Patients with ER+ or PR+, HER2 negative, breast cancer are candidates to participate.

After completion of chemotherapy all patients will have a breast surgery to assess pathologic response.

Complete pathologic response is defined as the abscence of malignant cells in breast tissue and lymph nodes. The presence of DCIS is considered as pCR

Condition Intervention Phase
Locally Advanced Malignant Neoplasm
Drug: Metformin
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Clinical Phase II, Randomized, Double Blind Trial, to Evaluate the Efficacy of Metformin and Chemotherapy Versus Placebo Nad Chemotherapy in Neoadjuvant Setting for Locally Advanced Breast Cancer

Resource links provided by NLM:

Further study details as provided by Instituto Nacional de Cancerologia de Mexico:

Primary Outcome Measures:
  • pathologic complete response [ Time Frame: pCR will be assesed after 24 weeks of treatment ]
    to assess the efficacy in terms of pahtologic complete response in patients with locally advanced breast cancer, treated with neoadjuvant chemotherapy based on Paclitaxel followed by FAC, combined with metformin or placebo

Secondary Outcome Measures:
  • Safety analysis [ Time Frame: after 24 treatment weeks' ]
    For safety analysis we are going to use NCTC criteria version 3.0

  • Assess clinical response at the end of paclitaxel and at the end of neoadjuvant chemotherapy [ Time Frame: after 24 treatment weeks' ]
    tumor measurements by caliper every cycle and by ultrasound at the end of chemotherapy

  • To correlate serum levels of insulin, protein C and HbA1 (after treatment) with clinical and pathologic response [ Time Frame: safter 24 treatment weeks' ]
    correlation between serum levels of insuline levels, HbA1 and PCR and PCR

Estimated Enrollment: 60
Study Start Date: April 2012
Estimated Study Completion Date: April 2014
Estimated Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Metformin
Patients will be receive 12 weeks of paclitaxel followed by 4 cycles of FAC combined with 500 mg/day of metformin p.o.
Drug: Metformin
metformin 500 mg/day po for 24 weeks.
Other Name: Dabex

Detailed Description:
Definitions Luminal A: tumors ER + PR + HER2 Negative and Ki67 <14% Luminal B: tumors ER +/-, PR +/-, HER2 negative and Ki67 >15% Complete pathologic response is defined as the abscence of malignant cells in breast tissue and lymph nodes. The presence of DCIS is considered as pCR

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Women older than 18 years old and younger than 70 years old

    • Invasive breast cancer confirmed by core biopsy, any histology
    • Tumor ≥2 cm and/or lymph node positive (proven by FNA)(T2-4b, N0-3, M0)
    • Must have ER/PR positive and HER2 negative
    • Must have full staging and extent disease and clinically and radiographically tumor measure
    • Without previous treatment for breast cancer (including surgery, hormonotherapy or chemotherapy)
  • Normal liver, kidney and blood tests
  • Performance Status ECOG 0-2 o Karnofsky ≥70%
  • Fasten glucose levels <125 mg/dl
  • Signed consent

Exclusion Criteria:

  • Previous use of metformin for any indication
  • Presence of Diabetes Mellitus
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01566799

Contact: Claudia Arce, MD, MSc +525556280400 ext 294
Contact: Julieta Santamaria, Nurse +525556280400 ext 116

Instituto Nacional Cancerologi
Mexico, Distrito Federal, Mexico, 14080
Sponsors and Collaborators
Instituto Nacional de Cancerologia de Mexico
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Principal Investigator: Claudia Arce, MD, MSc Instituto Nacional Canerologia
  More Information

Responsible Party: Claudia Arce Salinas, Medico Especialista, Instituto Nacional de Cancerologia de Mexico Identifier: NCT01566799     History of Changes
Other Study ID Numbers: MET-INCAN-1
Study First Received: March 22, 2012
Last Updated: March 29, 2012

Keywords provided by Instituto Nacional de Cancerologia de Mexico:
Locally advanced breast cancer
Neoadjuvant chemotherapy
Pathologic Complete Response

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on April 28, 2017